Sage Therapeutics(US:SAGE)2021-08-03 14:37Zuranolone Clinical Development Program - Zuranolone demonstrated a reduction of depressive symptoms seen within 72 hours[33] - Approximately 70% of participants with positive response to an initial 2-week 30 mg treatment in the SHORELINE Study required at most one additional zuranolone treatment during the 12-month study[33] - In the WATERFALL Study, the change from baseline in HAM-D total score on Day 15 favored zuranolone over placebo by -1.7 points (p=0.0141)[46] - In the SHORELINE Study (30 mg cohort), 42.9% of patients required only one course of treatment (no re-treatment)[78] - In the SHORELINE Study (30 mg cohort), 25.6% of patients required two courses of treatment[78] - In the SHORELINE Study (30 mg cohort), 11.9% of patients required three courses of treatment[78] - In the SHORELINE Study (30 mg cohort), 10.8% of patients required four courses of treatment[78] - In the SHORELINE Study (30 mg cohort), 8.8% of patients required five courses of treatment[78] - In the 199 patients who received zuranolone 50 mg only in SHORELINE study, approximately 80.5% achieved response and 43.2% achieved remission after the initial 2-week treatment period[71,74] Financial Status - Sage anticipates a cash balance of more than $1.7 billion at the end of 2021[162]